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Abstract. Stroke represents a major clinical problem with
limited available therapeutic treatments. Nitric oxide (NO)
and the enzymes that produce it are involved in the
pathogenesis of this disease. Here we investigated whether
the novel NO donor LA 419 was able to ameliorate the
consequences of stroke in an experimental model of global
ischemia. We observed a sharp increase in the amounts of
inducible NO synthase (iNOS) and nitrotyrosine in the
cerebral cortex of experimental rats and a moderate increase
of neuronal NO synthase (nNOS), as demonstrated by
immunohistochemistry, Western blotting, and enzymatic
activity assays. Treatment of these animals with LA 419
completely prevented ischemia-induced upregulation of
nitrergic markers. Magnetic resonance imaging of the
experimental brains showed a marked decrease in apparent
diffusion coefficient (ADC) following ischemia-reperfusion,
which was significantly corrected by pre-treatment with LA
419. These results clearly show that LA 419 is an efficient
modulator of NO-related pathophysiological events and
could eventually be used for the treatment of patients with
cerebrovascular pathologies.
Introduction
Stroke is one of the main causes of death and a major cause
of long-term disability in the western world. Indeed, stroke
accounted for more than 1 in every 15 deaths in the United
States in 2003 (http://www.americanheart.org). More than
80% of all strokes are caused by cerebral ischemia (1),
resulting in devastating neurological sequelae accompanied
by severe morphological and molecular alterations (2).
Since stroke is common and current drug therapies for the
management of stroke patients are limited (3), there is a need
for the identification of new targets and the development of
new drugs (4). In the last decade several studies have
examined the role of nitric oxide (NO) and nitric oxide
synthase (NOS) in cardiac and cerebral ischemia (5-7). From
these studies, it is becoming clear that both NO levels (4,8-10)
and NOS activity (11) are increased in the heart and brain
following ischemia, and that the nitrergic system is a good
target for neuroprotection during stroke incidents (12). 
The functional contributions of the different NOS isoforms
to cerebral and cardiac stroke have been studied with
genetically engineered mice where one of the isoforms had
been knocked out, and using specific biochemical inhibitors.
From these studies, we can conclude that inducible NOS
(iNOS) expression contributes to ischemic damage, both in
the brain (13) and in the heart (14). In contrast, endothelial
NOS (eNOS) is always protective and eNOS-null mice
suffered greater damage following brain (15) and heart (16)
ischemia than their wild-type littermates. In addition,
inhibitors of eNOS such as L-N-nitroarginine provoked
stroke in stroke-prone spontaneously hypertensive rats, as
well as in other rat strains (17). The impact of neuronal NOS
(nNOS) in stroke is more complex and seems to be context-
specific. For instance, while nNOS-null mice developed a
smaller infarct volume than control animals in models of
cerebral ischemia (18), they showed higher mortality and
heart remodeling following myocardial infarction (19).
Whether nNOS is protective or deleterious is also sex-
dependent (20,21).
LA 419 is a novel NO donor that has been designed to
treat clinical conditions associated with a reduced bio-
availability of NO (22). LA 419 has been shown to exert
heart anti-ischemic, anti-thrombotic, as well as anti-
atherosclerotic actions (22-24), but so far no studies have
been performed on the protective effects of this drug in
cerebral ischemia.
The aim of the present study was to determine the effects
of LA 419 treatment in a model of global brain ischemia by
immunohistochemistry, Western blotting, enzyme activity
assays, and magnetic resonance imaging (MRI) in the
absence and presence of the NO donor. The cerebral cortex
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was studied, since our previous study focused on this same
area (25). Very significant differences in the expression of
nNOS, iNOS, and nitrotyrosine, as well as in brain imaging,
after treatment with LA 419 of ischemic animals suggest that
this chemical may be useful to prevent and/or treat ischemic
damage.
Materials and methods
Animals. Male Wistar rats (n=56) provided by Harlan
(Barcelona, Spain) weighing 250-350 g were housed in a
conventional animal facility where the environmental
temperature and relative humidity were monitored and
controlled. The animals had free access to food and water
except when otherwise specified. The lighting schedule in the
animal facility was 12 h light/12 h dark. After a 1-week
quarantine period, animals included in the protocol were fasted
overnight before the study. All procedures were carried out
in accordance with the European Communities Council
Directive (86/609/EEC) on animal experiments, under a
protocol approved by the Animal Welfare Committee of the
Cajal Institute.
Administration of LA 419. After a food fasting period of 8 h,
LA 419 was given by oral gavage in a vehicle consisting of
1% Cremophor EL 27963, 1% Tween-80 and 0.5% Methocel
E-15 in distilled water at the indicated concentrations. The
calculated ED50 for LA 419 in rats is 28 μmol/kg (=7 mg/
kg) (Lácer, unpublished results). For our experiments we
chose a dose slightly higher (20 mg/kg) to ascertain proper
drug saturation.
Perfusion model of global cerebral ischemia. A perfusion
model of global cerebral ischemia was used as described
(26,27). Control rats (n=7), which were not subjected to
ischemia-reperfusion, were anesthetized with equithesin
(150 mg/kg chloral hydrate and 34 mg/kg pentobarbital) and
perfused intracardialy with 100 ml saline. The brains were
collected for either Western blotting and enzyme activity
assays (n=4), or followed by perfusion with 350 ml of
fixative solution as described below for immunohisto-
chemistry (n=3). 
The animals subjected to ischemia-reperfusion (n=21)
were perfused with the help of a peristaltic pump at 5 ml/
min via the left ventricle with an oxygenated buffered plasma
substitute (Hemoce, Hoechst Farma, Barcelona, Spain)
enriched with 11 mM glucose as described (26,27). The
perfusion protocol began with a 15-min ‘protection’ period in
which the perfusate had a high magnesium concentration
(10 mM) to prevent the activation of the NMDA receptors.
This was followed by a 15-min ‘adaptation’ period at a
physiological magnesium concentration (1.19 mM) and a
30-min ‘ischemia’ period during which the perfusate was
gassed with 95% N2 and 5% CO2 and contained no glucose.
After ischemia, animals were exposed to a ‘reperfusion’ period
that lasted 6, 8, or 12 h (n=7 per group), using the same
perfusion solution as in the ‘adaptation’ period. 
Frozen tissue fragments of cerebral cortex were homo-
genized, and the supernatants were prepared for Western
blotting and enzyme activity assay, or followed by perfusion
with fixative solution for immunohistochemistry, as described
below. 
Another group of rats (n=28) (identified as the treatment
animals) received the NO donor LA 419 (at 20 mg/kg of
body weight), by oral gavage 1 h prior to ischemia-
reperfusion, following the same protocol as above. This
group included treated non-ischemic controls (n=7) and 3
groups of rats (n=7 per group) subjected to 30-min ischemia
and 6, 8, or 12 h of reperfusion.
Antisera. Rabbit antisera against nNOS, iNOS, and
nitrotyrosine were produced in-house as previously described
(26). We also used a commercial mouse monoclonal iNOS
antibody (Transduction Laboratories, Lexington, KY, USA).
Immunohistochemical staining. Immunohistochemistry was
performed as described (27). Briefly, the brains were fixed
by transcardial perfusion with 350 ml 4% (w/v) para-
formaldehyde in 0.1 M phosphate buffer (PB), pH 7.4, at the
end of the experimental procedure. The brains were then
removed, cut into blocks, post-fixed for 3 h at room
temperature and cryoprotected by immersion in 30% (w/v)
sucrose in PB. Frozen serial coronal sections, 40-μm thick,
were cut with a Leitz sledge microtome, and free-floating
sections were processed by the avidin-biotin peroxidase
complex (ABC) technique to visualize nNOS, iNOS, and
nitrotyrosine immunoreactive sites. Photomicrographs were
captured with a digital camera (Polaroid DMC IE,
Cambridge, MA, USA) attached to a bright field microscope
(Axioplan 2, Zeiss, Jena, Germany). The images were
imported into Adobe Photoshop, version 5.5, at 300 dpi,
cropped and corrected for brightness and contrast but not
otherwise manipulated, and then transferred to Microsoft
PowerPoint 2000 for plate production.
Immunohistochemical controls. No immunolabeling was
observed when the primary antibodies were omitted or
replaced with an equivalent concentration of preimmune or
normal rabbit serum. The specificity of the nNOS antiserum
was demonstrated by incubating the tissue sections with the
primary antiserum preabsorbed (overnight at 4˚C) with 2 μg/
ml recombinant nNOS. The specificity of the iNOS antiserum
was shown by preabsorption with 10 nmol/ml of the
respective immunising peptide. The specificity of the
nitrotyrosine antiserum was demonstrated by preabsorption
with free nitrotyrosine at 100 nmol/ml. This procedure
abolished immunostaining in all cases.
Western blotting. Western blotting studies were performed as
previously described (26). Briefly, brains were removed at
various times during the experimental perfusion procedure,
or from control rats. Cortical tissues were homogenized.
Homogenates were centrifuged, and the supernatants
collected. Protein concentrations were determined by the
method of Bradford (28), using bovine serum albumin as
standard. Samples of supernatants were mixed 1:1 with 2X
sample buffer and denatured at 95˚C for 3 min. SDS poly-
acrylamide gel electrophoresis was performed in 7.5 or 10%
polyacrylamide gels with a 3.5% stacking gel and with 0.25 M
Tris-glycine, pH 8.3 as the electrolyte buffer in a Bio-Rad
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Mini-Protein II apparatus (Bio-Rad, Madrid, Spain). Proteins
were electroblotted at 1.5 mA/cm2 for 1 h onto 0.2-mm
polyvinylidene difluoride (PVDF) membranes (Immobilon-P,
Millipore, Bedford, MA, USA) by means of a semidry
transfer apparatus (Bio-Rad) for incubation with antibody.
Non-specific binding sites were blocked for 1 h at room
temperature with 5% (w/v) dried defatted milk and 0.1%
(v/v) Tween-20 in Tris-buffered saline (TBS), pH 7.6
(blocking solution). The membranes were then incubated
with dilutions of the antisera in blocking solution overnight
at 4˚C. After extensive washing in TBS, bound antibodies
were revealed by the enhanced chemiluminescence kit
including the appropriate secondary antibody conjugates
(Amersham Pharmacia Biotech, Cerdanyola, Spain)
according to the manufacturer's instructions. The membranes
were exposed to X-ray film and scanned with a computer-
assisted densitometer.
NOS activity assay. The activity of NOS in the supernatants
of the brain extracts prepared for Western blotting was
measured as the rate of conversion of radiolabeled arginine to
citrulline in the assay as described (29). Briefly, the samples
were incubated at 37˚C with [U14C]-L-arginine (Amersham)
in buffer containing 50 mM KH2PO4, 1 mM MgCl2, 0.2 mM
CaCl2, 50 mM L-valine, 1 mM L-citrulline, 20 μM L-arginine,
0.1 mM NADPH, 10 μM tetrahydrobiopterin and 1.5 mM
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Figure 1. Expression of nNOS and Ca2+-dependent NOS activity in control and ischemic animals in the absence and presence of NO donor LA 419.
Immunohistochemical staining for nNOS labels large interneurons (type I) in the cortex of control animals (A). After 30 min of ischemia and 8 h of
reperfusion, type II neurons (arrows) became immunoreactive for nNOS (B). Treatment with LA 419 reduced nNOS immunoreactivity in type II neurons at
the same time period (C). Bar = 60 μm. When the number of nNOS-IR type I (D) and type II (E) neurons were counted, differences were not significant in the
large interneurons (D), but were highly significant in type II cells (E). *Statistically significant differences with control (p<0.001); #statistically significant
differences with untreated animals at the same time of reperfusion (p<0.001). Representative Western blotting of cortex extracts from these animals (F) and
densitometer quantification corrected by ß-tubulin values (G) showed no significant differences in global nNOS expression. Biochemical analysis of Ca2+-
dependent NOS activity (H) showed no difference between treatments as well. Bars represent mean ± SEM of at least 3 independent repeats.
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dithiothreitol, in the presence or absence of L-NAME. The
addition of 2 mM ethylene glycol-bis(ß-aminoethyl ether)
(EGTA) was used to differentiate between Ca2+-dependent
and Ca2+-independent NOS activities. After 20 min of
incubation, the reaction was terminated by adding AG 50W-X8
resin (Bio-Rad) to remove unreacted arginine, and the
radioactivity remaining in the supernatant was counted in a
liquid scintillation counter (Wallac 1410, Pharmacia).
Magnetic resonance imaging. Brains of NO donor-treated
and untreated rats were analyzed by MRI as previously
described (26). Images were acquired in a Bruker Biospec
47/40 spectrometer, with a main field of 4.7 T and a 40-cm
bore. This magnet is equipped with an unshielded gradient
coil with a maximum strength of 372 mT/m. The RF coil,
acting as a transmitter and receiver, was a 30-mm-diameter
surface coil placed just on top of the head of the rat. Initially,
localization fast spin echo images were acquired both in the
coronal and in the sagittal directions, and a single coronal
slice was selected for imaging, located approximately 2.3 mm
anterior to the bregma. Diffusion-weighted images were
acquired with a 30x30 mm field of view, a slice thickness of
1 mm, and a 256x64 acquisition matrix, using a slice-
selective spin echo sequence, with one slice, two averages,
and five different values of the diffusion gradient, TE=50,
TR=200, T=20.56, and ‰=10 msec. Spatial resolution was
therefore 1,000 (slice thickness) x 469 x 117 μm. Apparent
diffusion coefficient (ADC) values were calculated by fitting
intensity values with a package included in the imaging
software ParaVision (Bruker, Ettlingen, Germany).
Statistical analysis. The number of neural structures
expressing nNOS, iNOS, or nitrotyrosine immunoreactivity
that were found in a columnar area of the cortex of 1.2 mm
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Figure 2. Expression of iNOS and Ca2+-independent NOS activity in control and ischemic animals in the absence and presence of NO donor LA 419.
Immunohistochemical staining for iNOS in control animals (A) was negligible. After 30 min of ischemia and 6 h of reperfusion, untreated animals presented a
granular staining pattern in the soma of cortical neurons (B), which disappeared in animals treated with the NO donor (C). Bar = 60 μm. The number of
iNOS-IR cells in defined areas of the cortex greatly increased after ischemia and reperfusion but was significantly reduced by treatment with LA 419 (D).
*Statistically significant differences with control (p<0.01); #statistically significant differences with untreated animals at the same time of reperfusion
(p<0.01). Representative Western blot of cortex extracts from these animals (E) and densitometer quantification corrected by ß-tubulin values (F) show a
significant increase after 30 min of ischemia and 8 h of reperfusion. This increase in iNOS-IR was prevented by treatment with the NO donor. Biochemical
analysis of Ca2+-independent NOS activity (G) showed a significant increase in activity following ischemia and 6 h of reperfusion (p<0.05 compared to
control) which was downregulated by LA 419 (p<0.01 compared to untreated animals). Bars represent mean ± SEM of at least 3 independent repeats.
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(length) by 2.5 mm (deep), was counted in 9 randomly
chosen areas per experimental animal. The data obtained
were analyzed by the Dunnet test. Western blotting data were
analysed by a t-test to compare groups using Prism 3.0
computer software. Analysis of the differences between
treated and untreated rats subjected to MRI was performed
by 2-way ANOVA. All results are expressed as mean ± SEM.
p values <0.05 were considered statistically significant.
Results
The brain cortices of treated and untreated animals were
studied by immunohistochemistry and Western blotting using
specific antibodies against nNOS, iNOS, and nitrotyrosine.
In addition, biochemical NOS activity was also assessed. The
results presented here describe specifically the effects of
ischemia-reperfusion on the fronto-parietal cortex; however
similar changes were found in other cortical areas.
Neuronal NOS and Ca2+-dependent activity. There are two
types of nNOS-immunoreactive (IR) neurons in the cortex of
the rat (Fig. 1A-C). The main difference is their larger (type I)
or smaller (type II, arrows in Fig. 2B) size, as previously
described (26). The number of neurons in the defined areas
(27 mm2/animal) was determined in all animals and
comparisons were made between treated and untreated
animals at different times of reperfusion (Fig. 1D and E). 
In the case of the large nNOS-IR neurons (type I), no
statistically significant differences were found when comparing
treated and untreated animals or the same group of animals at
different time points (Fig. 1A-D). However, the small nNOS-IR
neurons (type II) presented a notable behavior. The number
of type II neurons in control rats was very low (Fig. 1A and E).
The number of type II positive neurons increased steadily
after 6 or 8 h of reperfusion (p<0.001 compared to control) in
the untreated rats (Fig. 1B and E). On the other hand, treatment
with LA 419 resulted in a very significant reduction in the
number of type II nNOS-IR neurons in the rat cortex
(p<0.001 at 6 and 8 h compared to untreated animals at the
same time of reperfusion; Fig. 1C and E). Western blotting
for nNOS in these animals showed no statistically significant
change (Fig. 1F and G). No changes were observed when
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Figure 3. Expression of nitrotyrosine in control and ischemic animals in the absence and presence of NO donor LA 419. Immunohistochemical staining for
nitrotyrosine in control animals (A) was low. Following ischemia and 8 h of reperfusion nitrotyrosine-IR was found in the soma and apical dendrites of
pyramidal neurons (B). The increase in nitrotyrosine-IR was less apparent in the presence of LA 419 (C). Bar = 40 μm. The number of nitrotyrosine-IR cells
in defined areas of the cortex increased after ischemia and reperfusion but was significantly reduced by treatment with LA 419 (D). *Statistically significant
differences with control (p<0.001); #statistically significant differences with untreated animals at the same time of reperfusion (p<0.01). Representative
Western blot of cortex extracts from these animals (E) and densitometer quantification corrected by ß-tubulin values (F) showed a significant increase after 30 min
of ischemia and 8 h of reperfusion. This increase in nitrotyrosine-IR was prevented by treatment with the NO donor. Bars represent the mean ± SEM of at
least 3 independent repeats.
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comparing treated versus untreated control animals. The
production of NO by nNOS is a Ca2+-dependent enzymatic
activity whereas iNOS activity is Ca2+-independent (29).
Ca2+-dependent NOS activity in the cortex of ischemic rats
did not change when compared to normal controls or to NO
donor-treated animals (Fig. 1H), suggesting that the increase
in immunoreactive type II neurons may not have an important
contribution to total nNOS activity.
Inducible NOS and Ca2+-independent activity. The number of
iNOS-IR structures in the cortex of control animals was
practically non-existent (Fig. 2A and D). iNOS expression
increased greatly after ischemia showing a zenith after 6 h of
reperfusion (p<0.001) that slowly diminished over time but
was still high at 12 h (p<0.01) (Fig. 2D). The immuno-
reactive pattern for iNOS was characteristically granular and
located mainly in the neuronal soma and the wide proximal
dendritic processes (Fig. 2B). Both the number of iNOS-IR
neurons and the intensity of their immunoreactivity were
significantly decreased in the presence of LA 419 (Fig. 2C
and D). Western blots of protein extracts obtained from the
cortices of the experimental animals were in agreement with
the immunohistochemical data (Fig. 2E and F). Tissues
extracted after ischemia and 6 or 8 h of reperfusion presented
more intense iNOS-IR bands than control animals (p<0.01).
Treatment with the NO donor LA 419 reduced iNOS-IR back
to normal levels. These results were confirmed by enzymatic
assays (Fig. 2G). Ca2+-independent NOS activity increased at
6 h of reperfusion when compared with controls (p<0.05),
whereas treatment with LA 419 reduced Ca2+-independent
NOS activity to below basal levels (p<0.01 compared to
untreated ischemic rats). The same trend was observed after
8 and 12 h of reperfusion but the total intensity of the signal
was lower (data not shown).
Nitrotyrosine. Excessive production of NO leads, among
other things, to protein nitration, specifically at exposed
tyrosine residues (7). Therefore the presence of nitrotyrosine
can be used as a surrogate marker of pathologic NO
production. In our rat model of brain ischemia, nitrotyrosine-
IR was very low in the cerebral cortex of control animals
(Fig. 3A), but steadily increased after 6 and 8 h of
reperfusion following global ischemia, and came back to
normal levels after 12 h of reperfusion (Fig. 3B and D). The
increase in nitrotyrosine-IR was observed both in the neurons
(Fig. 3B) and in glial cells (results not shown). In many cases,
nitrotyrosine-IR neurons presented a morphology consistent
with neuronal degeneration (data not shown). As with iNOS,
the pathological increase in nitrotyrosine-IR was efficiently
prevented by treatment with LA 419 (Fig. 3C and D). Western
blot analyis of nitrotyrosine-positive bands predictably
showed a significant increase after ischemia and 8 h of
reperfusion (p<0.001), which did not appear in animals treated
with the drug (Fig. 3E and F). Similar patterns were obtained
at 6 and 12 h of reperfusion (data not shown).
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Figure 4. Coronal images of rat brain analyzed by MRI. As expressed by the scale to the right, colder colors represent higher ADC and warmer colors lower
ADC values. The upper row shows the brain of the same rat, which was not treated with NO-donor at different time periods during global ischemia (i) and
reperfusion (r). Numbers are in minutes. The lower row of images represents the brain of another rat, treated with NO-donor as described in Materials and
methods at the same periods of time.
Figure 5. Quantification of the ADC values obtained in the cortex of NO-
donor treated (squares) and untreated (circles) rats at different times of
ischemia (i) and reperfusion (r). Numbers represent minutes. Each point
represents the mean ± SD of 3 independent measurements. Statistically
significant differences with the same animal before the perfusion began (0),
expressed as 100%, are indicated with asterisks: *p<0.005, **p<0.001,
***p<0.0001.
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Magnetic resonance imaging in global ischemia. The brain
maps in control animals (before any treatment) showed a
mean apparent diffusion coefficient (ADC) value of 3.07±
0.08x10-6 cm2/sec (Fig. 4). The untreated control group
showed a notable decrease in ADC during ischemia and
reperfusion (Figs. 4 and 5), reaching significantly lower
values of ADC after 30 min of ischemia, even before the
reperfusion period began. For the animals treated with the
NO donor there was also a slight decline in ADC, but this
value did not reach statistically significant differences
compared with the control (same animals at time = 0) until
after 6 h of reperfusion (Figs. 4 and 5). Comparison of ADC
values in the cortex of both groups of animals was performed
by a 2-way ANOVA. Both groups were statistically different
with the following parameters; F=21.717 and p<0.0001.
Discussion
We have shown that the novel NO donor LA 419 reduces
ischemic damage in an experimental model of global brain
ischemia. We focused on the cerebral cortex and thus cannot
predict the effects of this drug in other regions. Previous
studies have produced apparently conflicting results on the
role played by NO in cerebral ischemia. On the one hand,
nNOS- and iNOS-deficient mice suffered smaller infarcts
than their wild-type littermates following experimental
ischemia (13,18), and something similar occurred when
animals were treated with NOS inhibitors (30-35). However,
the lack of NO elicited by either genetic manipulation or
NOS inhibitors had detrimental effects for normal brain
physiology, especially related to cerebral blood flow and
disturbed neuronal function (13,17,36). To note, the
administration of NO donors such as sodium nitroprusside,
DETA/NONOate, or 3-morpholinosydnonimine, also
reduces infarct size (37-39). This apparent controversy may
be resolved by considering the total levels of NO available in
the tissue at a particular time. It has been suggested that low
levels of NO are neuro-protective due to the beneficial effects
of NO on vasodilatation and normal neuronal function,
whereas high levels of NO may lead to the formation of free
radicals and deleterious biochemical modifications of cell
components (7). In addition, NO donors downregulate iNOS
expression and upregulate expression of eNOS (35,40). This
beneficial effect may be mediated by activation of the
glucocorticoid receptor and the glucocorticoid response
element, which would reduce iNOS expression (41), thus
avoiding the robust production of NO characteristic of this
NOS isoform.
In our global cerebral ischemia model, we have described
a modest upregulation of nNOS following ischemia and
reperfusion which was not followed by a significant increase
in Ca2+-dependent NOS enzymatic activity. This disconnection
between increased immunoreactivity and no change in
activity has been previously reported and may be due to a
lack of NADPH diaphorase activity in the newly synthesized
nNOS (42).
In contrast, iNOS immunoreactivity and Ca2+-independent
enzymatic NOS activity increased sharply after ischemia and
reperfusion, suggesting that this enzyme is mainly
responsible for the NO-related damage caused by cerebral
infarcts. Again, the NO donor LA 419 completely prevented
the pathological overexpression of iNOS as shown by
immunohistochemistry, Western blotting, and iNOS activity
assays. We have studied the effect of LA 419 on iNOS
expression in an in vitro cellular model of the transition from
monocyte to macrophage. The levels of iNOS were followed
by Western blotting at day 1 (adherent monocyte) and 3
(early macrophage) of the transition process. Treatment of the
cells with 5 μM LA 419 reduced iNOS expression by
50±17% at day 1 and by 44±10% at day 3 (unpublished
results).
Nitrotyrosine staining was mainly found in astroglia,
identifying this cell type as the most prone to protein
nitration in the brain. The high susceptibility of the astrocytes
to nitration has been described also in other pathologies (7).
In our global model, we have seen a clear decrease in
ADC following ischemia-reperfusion. This was previously
described by our group (26) and interpreted as a consequence
of the increase in cytotoxic intracellular edema caused by the
ischemia-induced breakdown of cell membrane transporters.
A decrease in ADC has been related to ischemic injury by
others as well (43).
In summary, we have shown that LA 419 prevented the
modifications induced by cerebral ischemia in the nitrergic
system of the brain and the resulting reduction in ADC,
suggesting a potential beneficial use of this NO donor in
stroke and in other conditions where an increase in NO
production is relevant. Further experiments are needed to
understand the mechanism of action of this new drug and
whether it may be useful for clinical treatment. 
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